<Summary id="CDR0000062897" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Penile cancer treatment options include surgery and radiation therapy depending upon tumor size, location, invasiveness, and stage. Get detailed information about the treatment of newly diagnosed and recurrent penile cancer in this summary for clinicians.</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/penile/hp/penile-treatment-pdq">Penile Cancer (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/penile/patient/penile-treatment-pdq">Penile Cancer (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000038214">penile cancer</TermRef></MainTopics><SummaryAbstract><Para id="_206">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of penile cancer. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_207">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>penile cancer</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Penile Cancer Treatment (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Penile Cancer Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Penile Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Penile Cancer</Title><SummarySection id="_180"><Title>Incidence and Mortality</Title><Para id="_131">Estimated new cases and deaths from penile  (and other male genital) cancer in the United States in 2025:<Reference refidx="1"/></Para><ItemizedList id="_132" Style="bullet"><ListItem>New cases: 2,190.</ListItem><ListItem>Deaths: 510.</ListItem></ItemizedList></SummarySection><SummarySection id="_196"><Title>Risk Factors</Title><Para id="_197">
Penile cancer is rare in most developed nations, including the United States, where the incidence rate is less than 1 per 100,000 men per year.  Some studies suggest an association between human papillomavirus (HPV) infection and penile cancer.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Observational studies have shown a lower prevalence of penile HPV in men who have been circumcised (odds ratio, 0.37; 95% confidence interval,  0.16–0.85).<Reference refidx="6"/>  Some, but not all, observational studies also suggest that male newborn circumcision is associated with a decreased risk of penile cancer.<Reference refidx="7"/><Reference refidx="8"/>  According to  published data,  if the relationship is causal, the number needed to treat was about 909 circumcisions to prevent a single case of invasive penile cancer.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_198"><Title>Treatment Overview</Title><Para id="_199">When diagnosed early (<SummaryRef href="CDR0000062897#_122" url="/types/penile/hp/penile-treatment-pdq">stage 0</SummaryRef>, <SummaryRef href="CDR0000062897#_39" url="/types/penile/hp/penile-treatment-pdq">stage I</SummaryRef>, and <SummaryRef href="CDR0000062897#_51" url="/types/penile/hp/penile-treatment-pdq">stage II</SummaryRef>), penile cancer is highly curable. 
Curability decreases sharply for <SummaryRef href="CDR0000062897#_58" url="/types/penile/hp/penile-treatment-pdq">stage III</SummaryRef> and <SummaryRef href="CDR0000062897#_69" url="/types/penile/hp/penile-treatment-pdq">stage IV</SummaryRef> disease.  Because of the rarity of
this cancer in the United States, clinical trials specifically for penile
cancer are infrequent.  Patients with stage III and stage IV cancer are candidates
for phase I and phase II clinical trials testing new drugs, biological therapy, or surgical
techniques to improve local control and distant metastases.
</Para><Para id="_200">The selection of treatment depends on the following tumor characteristics:<Reference refidx="10"/><Reference refidx="11"/></Para><ItemizedList id="_201" Style="bullet"><ListItem>Size.</ListItem><ListItem>Location.</ListItem><ListItem>Invasiveness.</ListItem><ListItem>Stage.</ListItem></ItemizedList><SummarySection id="_231"><Title>Fluorouracil dosing</Title><SummarySection id="_sm_CDR0000813769_3"><Para id="_sm_CDR0000813769_4">The <GeneName>DPYD</GeneName> gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in <GeneName>DPYD</GeneName>, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.<Reference refidx="12"/><Reference refidx="13"/> Patients with the <GeneName>DPYD*2A</GeneName> variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other <GeneName>DPYD</GeneName> variants have been identified,  with a range of clinical effects.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on  the patient's <GeneName>DPYD</GeneName> genotype and number of functioning <GeneName>DPYD</GeneName> alleles.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/> <GeneName>DPYD</GeneName> genetic testing costs less than $200, but insurance coverage varies due to  a lack of national guidelines.<Reference refidx="18"/> In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.<Reference refidx="19"/></Para></SummarySection></SummarySection></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. <ExternalRef xref="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf">Available online</ExternalRef>. Last accessed January 16, 2025.</Citation><Citation idx="2" PMID="11423255" MedlineID="21315857">Del Mistro A, Chieco Bianchi L: HPV-related neoplasias in HIV-infected individuals. Eur J Cancer 37 (10): 1227-35, 2001.</Citation><Citation idx="3" PMID="10510097" MedlineID="99440191">Griffiths TR, Mellon JK: Human papillomavirus and urological tumours: I. Basic science and role in penile cancer. BJU Int 84 (5): 579-86, 1999.</Citation><Citation idx="4" PMID="10478673" MedlineID="99405778">Poblet E, Alfaro L, Fernander-Segoviano P, et al.: Human papillomavirus-associated penile squamous cell carcinoma in HIV-positive patients. Am J Surg Pathol 23 (9): 1119-23, 1999.</Citation><Citation idx="5" PMID="9060069" MedlineID="97213304">Frisch M, van den Brule AJ, Jiwa NM, et al.: HPV-16-positive anal and penile carcinomas in a young man--anogenital 'field effect' in the immunosuppressed male? Scand J Infect Dis 28 (6): 629-32, 1996.</Citation><Citation idx="6" PMID="11948269" MedlineID="21945851">Castellsagué X, Bosch FX, Muñoz N, et al.: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346 (15): 1105-12, 2002.</Citation><Citation idx="7" PMID="10699138" MedlineID="20165351">Schoen EJ, Oehrli M, Colby C, et al.: The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics 105 (3): E36, 2000.</Citation><Citation idx="8" PMID="8634956" MedlineID="96258155">Neonatal circumcision revisited. Fetus and Newborn Committee, Canadian Paediatric Society. CMAJ 154 (6): 769-80, 1996.</Citation><Citation idx="9" PMID="10617731" MedlineID="20102811">Christakis DA, Harvey E, Zerr DM, et al.: A trade-off analysis of routine newborn circumcision. Pediatrics 105 (1 Pt 3): 246-9, 2000.</Citation><Citation idx="10">Mark JR, Hurwitz M, Gomella LG: Cancer of the urethra and penis. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 11th ed. Wolters Kluwer Health, 2019, pp 1136-44.</Citation><Citation idx="11">Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Lippincott-Raven Publishers, 1998, pp 1717-1732.</Citation><Citation idx="12" PMID="34506675">Sharma BB, Rai K, Blunt H, et al.: Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. Oncologist 26 (12): 1008-1016, 2021.</Citation><Citation idx="13" PMID="27569869">Lam SW, Guchelaar HJ, Boven E: The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev 50: 9-22, 2016.</Citation><Citation idx="14" PMID="33410339">Shakeel F, Fang F, Kwon JW, et al.: Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy. Pharmacogenomics 22 (3): 145-155, 2021.</Citation><Citation idx="15" PMID="29152729">Amstutz U, Henricks LM, Offer SM, et al.: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 103 (2): 210-216, 2018.</Citation><Citation idx="16" PMID="30348537">Henricks LM, Lunenburg CATC, de Man FM, et al.: DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19 (11): 1459-1467, 2018.</Citation><Citation idx="17" PMID="34996412">Lau-Min KS, Varughese LA, Nelson MN, et al.: Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. BMC Cancer 22 (1): 47, 2022.</Citation><Citation idx="18" PMID="35668003">Brooks GA, Tapp S, Daly AT, et al.: Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. Clin Colorectal Cancer 21 (3): e189-e195, 2022.</Citation><Citation idx="19" PMID="36821823">Baker SD, Bates SE, Brooks GA, et al.: DPYD Testing: Time to Put Patient Safety First. J Clin Oncol 41 (15): 2701-2705, 2023.</Citation></ReferenceSection></SummarySection><SummarySection id="_4"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Penile Cancer</Title><Para id="_5">Virtually all penile carcinomas are of squamous cell origin and include the following subtypes: 
</Para><ItemizedList id="_105" Style="bullet"><ListItem>Verrucous carcinoma.<Reference refidx="1"/></ListItem><ListItem>	Warty carcinoma (verruciform).<Reference refidx="2"/></ListItem><ListItem>Basaloid carcinoma.<Reference refidx="3"/> </ListItem></ItemizedList><Para id="_130">Although they are less common subtypes, warty carcinoma and basaloid carcinoma appear to be more highly associated with human papillomaviruses (HPV), particularly HPV 16, than typical squamous cell carcinoma or verrucous carcinoma of the penis.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> </Para><Para id="_106">Neuroendocrine carcinomas can also be seen.<Reference refidx="6"/></Para><ReferenceSection><Citation idx="1" PMID="7822496">Schwartz RA: Verrucous carcinoma of the skin and mucosa. J Am Acad Dermatol 32 (1): 1-21; quiz 22-4, 1995.</Citation><Citation idx="2" PMID="11342782" MedlineID="21240070">Bezerra AL, Lopes A, Landman G, et al.: Clinicopathologic features and human papillomavirus dna prevalence of warty and squamous cell carcinoma of the penis. Am J Surg Pathol 25 (5): 673-8, 2001.</Citation><Citation idx="3" PMID="9630184" MedlineID="98292136">Cubilla AL, Reuter VE, Gregoire L, et al.: Basaloid squamous cell carcinoma: a distinctive human papilloma virus-related penile neoplasm: a report of 20 cases. Am J Surg Pathol 22 (6): 755-61, 1998.</Citation><Citation idx="4" PMID="7473819">Gregoire L, Cubilla AL, Reuter VE, et al.: Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst 87 (22): 1705-9, 1995.</Citation><Citation idx="5" PMID="11583947">Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 (4): 1211-8, 2001.</Citation><Citation idx="6" PMID="9072615" MedlineID="97188843">Vadmal MS, Steckel J, Teichberg S, et al.: Primary neuroendocrine carcinoma of the penile urethra. J Urol 157 (3): 956-7, 1997.</Citation></ReferenceSection></SummarySection><SummarySection id="_6"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Penile Cancer</Title><SummarySection id="_163"><Title>American Joint Committee on Cancer (AJCC) Stage Groupings and Definitions of TNM</Title><Para id="_179">The AJCC has designated staging by TNM
(tumor, node, metastasis) classification to define penile cancer.<Reference refidx="1"/></Para><Table id="_214"><Title>Definitions of TNM Stages 0is and 0a<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="21.97%"/><ColSpec ColName="col2" ColNum="2" ColWidth="30.10%"/><ColSpec ColName="col3" ColNum="3" ColWidth="47.91%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">TNM</entry><entry Align="Center">Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; cN = clinical N;  PeIN = penile intraepithelial neoplasia; pN = pathological N.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Amin MB, Edge SB,  Greene FL, et al., eds.: <Emphasis>AJCC Cancer Staging Manual</Emphasis>. 8th ed. New York, NY: Springer, 2017, pp 701–14.</entry></Row></TFoot><TBody><Row><entry MoreRows="2">0is</entry><entry MoreRows="2">Tis, N0, M0</entry><entry>Tis = Carcinoma <Emphasis>in situ</Emphasis> (PeIN).</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0</Emphasis>, no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="2">0a</entry><entry MoreRows="2">Ta, N0, M0</entry><entry>Ta = Noninvasive localized squamous cell carcinoma.</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0</Emphasis>, no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_215"><Title>Definitions of TNM Stage I<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="21.23%"/><ColSpec ColName="col2" ColNum="2" ColWidth="28.45%"/><ColSpec ColName="col3" ColNum="3" ColWidth="50.31%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">TNM</entry><entry Align="Center">Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; cN = clinical N;  pN = pathological N.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Amin MB, Edge SB,  Greene FL, et al., eds.: <Emphasis>AJCC Cancer Staging Manual</Emphasis>. 8th ed. New York, NY: Springer, 2017, pp 701–14.</entry></Row></TFoot><TBody><Row><entry MoreRows="2">I</entry><entry MoreRows="2">T1a, N0, M0</entry><entry>T1a = Tumor is without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0</Emphasis>,  no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_216"><Title>Definitions of TNM Stages IIA and IIB<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="21.50%"/><ColSpec ColName="col2" ColNum="2" ColWidth="26.66%"/><ColSpec ColName="col3" ColNum="3" ColWidth="51.82%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">TNM</entry><entry Align="Center">Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; cN = clinical N;  pN = pathological N.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Amin MB, Edge SB,  Greene FL, et al., eds.: <Emphasis>AJCC Cancer Staging Manual</Emphasis>. 8th ed. New York, NY: Springer, 2017, pp 701–14.</entry></Row></TFoot><TBody><Row><entry MoreRows="5">IIA</entry><entry MoreRows="2">T1b, N0, M0</entry><entry>T1b = Tumor exhibits lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0</Emphasis>, no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="2">T2, N0, M0</entry><entry>T2 = Tumor invades into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion.</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0</Emphasis>,  no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="2">IIB</entry><entry MoreRows="2">T3, N0, M0</entry><entry>T3 = Tumor invades into corpora cavernosum (including tunica albuginea) with or without urethral invasion.</entry></Row><Row><entry>N0 = <Emphasis>cN0</Emphasis>, no palpable or visibly enlarged inguinal lymph nodes; <Emphasis>pN0,</Emphasis>  no lymph node metastasis.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_217"><Title>Definitions of TNM Stages IIIA and IIIB<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="22.17%"/><ColSpec ColName="col2" ColNum="2" ColWidth="26.60%"/><ColSpec ColName="col3" ColNum="3" ColWidth="51.21%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">TNM</entry><entry Align="Center">Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; cN = clinical N; ENE = extranodal extension;  pN = pathological N.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Amin MB, Edge SB,  Greene FL, et al., eds.: <Emphasis>AJCC Cancer Staging Manual</Emphasis>. 8th ed. New York, NY: Springer, 2017, pp 701–14.</entry></Row></TFoot><TBody><Row><entry MoreRows="6">IIIA</entry><entry MoreRows="6">T1–3, N1, M0</entry><entry>T1 = <Emphasis>Glans:</Emphasis> Tumor invades lamina propria; <Emphasis>Foreskin:</Emphasis> Tumor invades dermis, lamina propria, or dartos fascia; <Emphasis>Shaft:</Emphasis> Tumor invades connective tissue between epidermis and corpora regardless of location; <Emphasis>All sites</Emphasis> with or without lymphovascular invasion or perineural invasion and is or is not high grade.</entry></Row><Row><entry>–T1a = Tumor is without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>–T1b = Tumor exhibits lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>T2 = Tumor invades into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion.</entry></Row><Row><entry>T3 = Tumor invades into corpora cavernosum (including tunica albuginea) with or without urethral invasion.</entry></Row><Row><entry>N1 = <Emphasis>cN1</Emphasis>, palpable mobile unilateral inguinal lymph node; <Emphasis>pN1</Emphasis>, ≤2 unilateral inguinal metastases, no ENE.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="6">IIIB</entry><entry MoreRows="6">T1–3, N2, M0</entry><entry>T1 = <Emphasis>Glans:</Emphasis> Tumor invades lamina propria; <Emphasis>Foreskin:</Emphasis> Tumor invades dermis, lamina propria, or dartos fascia; <Emphasis>Shaft:</Emphasis> Tumor invades connective tissue between epidermis and corpora regardless of location; <Emphasis>All sites</Emphasis> with or without lymphovascular invasion or perineural invasion and is or is not high grade.</entry></Row><Row><entry>–T1a = Tumor is without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>–T1b = Tumor exhibits lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>T2 = Tumor invades into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion.</entry></Row><Row><entry>T3 = Tumor invades into corpora cavernosum (including tunica albuginea) with or without urethral invasion.</entry></Row><Row><entry>N2 = <Emphasis>cN2</Emphasis>, palpable mobile ≥ unilateral inguinal nodes or bilateral inguinal lymph nodes; <Emphasis>pN2</Emphasis>, ≥3 unilateral inguinal metastases or bilateral metastases, no ENE.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_218"><Title>Definitions of TNM Stage IV<Superscript>a</Superscript></Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="22.57%"/><ColSpec ColName="col2" ColNum="2" ColWidth="26.63%"/><ColSpec ColName="col3" ColNum="3" ColWidth="50.79%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">TNM</entry><entry Align="Center">Description</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">T = primary tumor; N = regional lymph node; M = distant metastasis; cN = clinical N; ENE = extranodal extension;   PeIN = penile intraepithelial neoplasia; pN = pathological N.</entry></Row><Row><entry NameEnd="col3" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Amin MB, Edge SB,  Greene FL, et al., eds.: <Emphasis>AJCC Cancer Staging Manual</Emphasis>. 8th ed. New York, NY: Springer, 2017, pp 701–14.</entry></Row></TFoot><TBody><Row><entry MoreRows="35">IV</entry><entry MoreRows="11">T4, Any N, M0</entry><entry>T4 = Tumor invades into adjacent structures (i.e., scrotum, prostate, pubic bone).</entry></Row><Row><entry>cNX = Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>cN0 = No palpable or visibly enlarged inguinal lymph nodes.</entry></Row><Row><entry>cN1 = Palpable mobile unilateral inguinal lymph node.</entry></Row><Row><entry>cN2 = Palpable mobile ≥ unilateral inguinal nodes or bilateral inguinal lymph nodes.</entry></Row><Row><entry>cN3 = Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.</entry></Row><Row><entry>pNX = Lymph node metastasis cannot be established.</entry></Row><Row><entry>pN0 = No lymph node metastasis.</entry></Row><Row><entry>pN1 = ≤2 unilateral inguinal metastases, no ENE.</entry></Row><Row><entry>pN2 = ≥3 unilateral inguinal metastases or bilateral metastases, no ENE.</entry></Row><Row><entry>pN3 = ENE of lymph node metastases or pelvic lymph node metastases.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="11">Any T, N3, M0</entry><entry>TX = Primary tumor cannot be assessed.</entry></Row><Row><entry>T0 = No evidence of primary tumor.</entry></Row><Row><entry>Tis = Carcinoma <Emphasis>in situ</Emphasis> (PeIN).</entry></Row><Row><entry>Ta = Noninvasive localized squamous cell carcinoma.</entry></Row><Row><entry>T1 = <Emphasis>Glans:</Emphasis> Tumor invades lamina propria; <Emphasis>Foreskin:</Emphasis> Tumor invades dermis, lamina propria, or dartos fascia; <Emphasis>Shaft:</Emphasis> Tumor invades connective tissue between epidermis and corpora regardless of location; <Emphasis>All sites</Emphasis> with or without lymphovascular invasion or perineural invasion and is or is not high grade.</entry></Row><Row><entry>–T1a = Tumor is without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>–T1b = Tumor exhibits lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid).</entry></Row><Row><entry>T2 = Tumor invades into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion.</entry></Row><Row><entry>T3 = Tumor invades into corpora cavernosum (including tunica albuginea) with or without urethral invasion.</entry></Row><Row><entry>T4 = Tumor invades into adjacent structures (i.e., scrotum, prostate, pubic bone).</entry></Row><Row><entry>N3 = <Emphasis>cN3</Emphasis>, palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral; <Emphasis>pN3</Emphasis>, ENE of lymph node metastases or pelvic lymph node metastases.</entry></Row><Row><entry>M0 = No distant metastasis.</entry></Row><Row><entry MoreRows="11">Any T, Any N, M1</entry><entry>Any T = See descriptions above in this table, stage IV,  Any T, N3, M0.</entry></Row><Row><entry>cNX = Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>cN0 = No palpable or visibly enlarged inguinal lymph nodes.</entry></Row><Row><entry>cN1 = Palpable mobile unilateral inguinal lymph node.</entry></Row><Row><entry>cN2 = Palpable mobile ≥2 unilateral inguinal nodes or bilateral inguinal lymph nodes.</entry></Row><Row><entry>cN3 = Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.</entry></Row><Row><entry>pNX = Lymph node metastasis cannot be established.</entry></Row><Row><entry>pN0 = No lymph node metastasis.</entry></Row><Row><entry>pN1 = ≤2 unilateral inguinal metastases, no ENE.</entry></Row><Row><entry>pN2 = ≥3 unilateral inguinal metastases or bilateral metastases, no ENE.</entry></Row><Row><entry>pN3 = ENE of lymph node metastases or pelvic lymph node metastases.</entry></Row><Row><entry>M1 = Distant metastasis present.</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation></ReferenceSection></SummarySection><SummarySection id="_122"><SectMetaData><SpecificDiagnosis ref="CDR0000566317">stage 0 penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Stage 0 Penile Cancer</Title><Para id="_184"><Strong>Stage 0 penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_124" Style="bullet"><ListItem>Tis, N0, M0</ListItem><ListItem>Ta, N0, M0</ListItem></ItemizedList><Para id="_125">Carcinoma <Emphasis>in situ</Emphasis> of the penis is referred to as erythroplasia of Queyrat when it occurs on the glans, and Bowen disease when it occurs on the penile shaft.  These precursor lesions progress to invasive squamous cell carcinoma in 5% to 15% of cases.  In case series studies, human papillomavirus DNA has been detected in most of these lesions.<Reference refidx="2"/><Reference refidx="3"/> With no data from clinical trials in this disease stage, treatment recommendations are largely based on case reports and case series involving limited numbers of patients.</Para><Para id="_126"><Strong>Treatment options:
</Strong></Para><OrderedList id="_127" Style="Arabic"><ListItem>Surgical excision can result in scarring, deformity, and impaired function.  To minimize these effects, Mohs micrographic surgery, which involves the excision of successive horizontal layers of tissue with microscopic examination of each layer in frozen section, has been used in patients with <Emphasis>in situ</Emphasis> and invasive penile cancers.<Reference refidx="4"/><Reference refidx="5"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem><ListItem>Topical application of fluorouracil cream has been effective in cases of erythroplasia of Queyrat <Reference refidx="6"/> and Bowen disease.<Reference refidx="7"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem><ListItem>	Imiquimod 5% cream is a topical immune response modifier that has been effective with good cosmetic and functional results.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem><ListItem>Laser therapy with Nd:YAG or CO<Subscript>2</Subscript> lasers has also resulted in excellent cosmetic results.<Reference refidx="11"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem><ListItem>Cryosurgery has resulted in good cosmetic results in patients with erythroplasia of Queyrat and verrucous penile carcinoma.<Reference refidx="12"/><Reference refidx="13"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</ListItem></OrderedList><SummarySection id="_TrialSearch_122_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_122_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation><Citation idx="2" PMID="7637047">Cupp MR, Malek RS, Goellner JR, et al.: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 154 (3): 1024-9, 1995.</Citation><Citation idx="3" PMID="11583947">Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 (4): 1211-8, 2001.</Citation><Citation idx="4" PMID="3999220" MedlineID="85211096">Mohs FE, Snow SN, Messing EM, et al.: Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 133 (6): 961-6, 1985.</Citation><Citation idx="5" PMID="2040751">Moritz DL, Lynch WS: Extensive Bowen's disease of the penile shaft treated with fresh tissue Mohs micrographic surgery in two separate operations. J Dermatol Surg Oncol 17 (4): 374-8, 1991.</Citation><Citation idx="6" PMID="991073">Goette DK, Carson TE: Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. Cancer 38 (4): 1498-502, 1976.</Citation><Citation idx="7" PMID="936382">Tolia BM, Castro VL, Mouded IM, et al.: Bowen's disease of shaft of penis. Successful treatment with 5-fluorouracil. Urology 7 (6): 617-9, 1976.</Citation><Citation idx="8" PMID="14616803">Danielsen AG, Sand C, Weismann K: Treatment of Bowen's disease of the penis with imiquimod 5% cream. Clin Exp Dermatol 28 (Suppl 1): 7-9, 2003.</Citation><Citation idx="9" PMID="14616802">Micali G, Nasca MR, Tedeschi A: Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin Exp Dermatol 28 (Suppl 1): 4-6, 2003.</Citation><Citation idx="10" PMID="11907505">Schroeder TL, Sengelmann RD: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 46 (4): 545-8, 2002.</Citation><Citation idx="11" PMID="11586199">van Bezooijen BP, Horenblas S, Meinhardt W, et al.: Laser therapy for carcinoma in situ of the penis. J Urol 166 (5): 1670-1, 2001.</Citation><Citation idx="12" PMID="12187233">Michelman FA, Filho AC, Moraes AM: Verrucous carcinoma of the penis treated with cryosurgery. J Urol 168 (3): 1096-7, 2002.</Citation><Citation idx="13" PMID="7073983">Sonnex TS, Ralfs IG, Plaza de Lanza M, et al.: Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery. Br J Dermatol 106 (5): 581-4, 1982.</Citation></ReferenceSection></SummarySection><SummarySection id="_39"><SectMetaData><SpecificDiagnosis ref="CDR0000038222">stage I penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Stage I Penile Cancer</Title><Para id="_185"><Strong>Stage I penile cancer is defined by the following TNM classification:<Reference refidx="1"/></Strong></Para><ItemizedList id="_87" Style="bullet"><ListItem>T1a, N0, M0</ListItem></ItemizedList><Para id="_41">Stage I penile cancer is curable.<Reference refidx="2"/>
</Para><Para id="_42"><Strong>Treatment options:
</Strong></Para><OrderedList id="_79" Style="Arabic"><ListItem>For lesions limited to the foreskin, wide local excision with circumcision may
be adequate therapy for control.
</ListItem><ListItem>For infiltrating tumors of the glans with or without involvement of the
adjacent skin, the choice of therapy is dictated by tumor size, extent of
infiltration, and degree of tumor destruction of normal tissue.  Equivalent
therapeutic options include:
<ItemizedList id="_47" Style="bullet"><ListItem>Penile amputation.<Reference refidx="3"/>
</ListItem>
<ListItem>Radiation  therapy (i.e., external-beam radiation therapy and  brachytherapy).<Reference refidx="4"/><Reference refidx="5"/>
</ListItem>
<ListItem>Microscopically controlled surgery.<Reference refidx="6"/>
</ListItem>
</ItemizedList></ListItem><ListItem>Nd:YAG laser therapy has offered excellent control/cure with preservation of
cosmetic appearance and sexual function (under clinical evaluation).<Reference refidx="7"/><Reference refidx="8"/>  
</ListItem></OrderedList><Para id="_50">Because of the high incidence of microscopic node metastases, elective
adjunctive inguinal dissection of clinically uninvolved (negative) lymph nodes
in conjunction with amputation is often used for patients with poorly
differentiated tumors.  Lymphadenectomy  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.  For these reasons, opinions vary on its use.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>
</Para><SummarySection id="_TrialSearch_39_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_39_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3">Lynch DF, Pettaway CA: Tumors of the penis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Saunders, 2002, pp 2945-2947.</Citation><Citation idx="4">Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Lippincott-Raven Publishers, 1998, pp 1717-1732.</Citation><Citation idx="5" PMID="8454480" MedlineID="93202967">McLean M, Akl AM, Warde P, et al.: The results of primary radiation therapy in the management of squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 25 (4): 623-8, 1993.</Citation><Citation idx="6" PMID="3999220" MedlineID="85211096">Mohs FE, Snow SN, Messing EM, et al.: Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 133 (6): 961-6, 1985.</Citation><Citation idx="7">Smith JA Jr.: Lasers in clinical urologic surgery. In: Dixon JA, ed.: Surgical Application of Lasers. 2nd ed. Year Book Medical Publishers, Inc., 1987, pp 218-237.</Citation><Citation idx="8" PMID="1593683" MedlineID="92277742">Horenblas S, van Tinteren H, Delemarre JF, et al.: Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 147 (6): 1533-8, 1992.</Citation><Citation idx="9" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="10" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="11" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="12" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation></ReferenceSection></SummarySection><SummarySection id="_51"><SectMetaData><SpecificDiagnosis ref="CDR0000038233">stage II penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Stage II Penile Cancer</Title><Para id="_186"><Strong>Stage II penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_88" Style="bullet"><ListItem>T1b, N0, M0</ListItem><ListItem>T2, N0, M0</ListItem><ListItem>T3, N0, M0</ListItem></ItemizedList><Para id="_53"><Strong>Treatment options:
</Strong></Para><OrderedList id="_230" Style="Arabic">
     <ListItem>Stage II penile cancer is most frequently managed by penile amputation for
local control.  Whether the amputation is partial, total, or radical will
depend on the extent and location of the neoplasm.  External-beam radiation therapy and brachytherapy with
surgical salvage are alternative approaches.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/></ListItem><ListItem>Nd:YAG laser therapy has been used to preserve the penis in selected patients
with small lesions (under clinical evaluation).<Reference refidx="7"/></ListItem></OrderedList><Para id="_57">Because of the high incidence of microscopic node metastases, elective
adjunctive dissection of clinically uninvolved (negative) lymph nodes in
conjunction with amputation is often used for patients with poorly
differentiated tumors.   Lymphadenectomy  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/>
</Para><Para id="_142">To reduce the morbidity associated with prophylactic lymphadenectomy, dynamic sentinel node biopsy is used in patients with stage T2 clinically node-negative penile cancer.  One retrospective, single-institution study of 22 patients reported a  false-negative rate of 11%.<Reference refidx="12"/></Para><SummarySection id="_TrialSearch_51_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_51_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3">Schellhammer PF, Spaulding JT: Carcinoma of the penis. In: Paulson DF, ed.: Genitourinary Surgery. Vol. 2. Churchill Livingston, 1984, pp 629-654.</Citation><Citation idx="4">Johnson DE, Lo RK: Tumors of the penis, urethra, and scrotum. In: deKernion JB, Paulson DF, eds.: Genitourinary Cancer Management. Lea and Febiger, 1987, pp 219-258.</Citation><Citation idx="5" PMID="8454480" MedlineID="93202967">McLean M, Akl AM, Warde P, et al.: The results of primary radiation therapy in the management of squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 25 (4): 623-8, 1993.</Citation><Citation idx="6" PMID="15890588">Crook JM, Jezioranski J, Grimard L, et al.: Penile brachytherapy: results for 49 patients. Int J Radiat Oncol Biol Phys 62 (2): 460-7, 2005.</Citation><Citation idx="7" PMID="1593683" MedlineID="92277742">Horenblas S, van Tinteren H, Delemarre JF, et al.: Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 147 (6): 1533-8, 1992.</Citation><Citation idx="8" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="9" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="10" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="11" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation><Citation idx="12" PMID="16360457">Perdonà S, Autorino R, De Sio M, et al.: Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. Urology 66 (6): 1282-6, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_58"><SectMetaData><SpecificDiagnosis ref="CDR0000038243">stage III penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Stage III Penile Cancer</Title><Para id="_187"><Strong>Stage III penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_89" Style="bullet"><ListItem>T1–3, N1, M0</ListItem><ListItem>T1–3, N2, M0</ListItem></ItemizedList><Para id="_60">Inguinal adenopathy in patients with penile cancer is common but may be the
result of infection rather than neoplasm.  If palpable enlarged lymph nodes
exist 3 or more weeks after removal of the infected primary lesion and completion of a
course of antibiotic therapy, bilateral inguinal lymph node dissection should
be performed.
</Para><Para id="_61">In cases of proven regional inguinal lymph node metastasis without evidence of
distant spread, bilateral ilioinguinal dissection is the treatment of
choice.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Because many patients with positive lymph nodes are not
cured, clinical trials may be appropriate.
</Para><Para id="_62"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_83" Style="Arabic"><ListItem>Clinically evident regional lymph node metastasis without evidence of
distant spread is an indication for bilateral ilioinguinal lymph node
dissection after penile amputation.<Reference refidx="6"/></ListItem><ListItem>Radiation therapy may be considered as an alternative to lymph node
dissection in patients who are not surgical candidates.</ListItem><ListItem>Postoperative radiation therapy may decrease incidence of inguinal recurrences.</ListItem><ListItem>Clinical trials using radiosensitizers or cytotoxic drugs are appropriate.  A
combination of vincristine, bleomycin, and methotrexate has been effective as
both neoadjuvant and adjuvant therapy.<Reference refidx="7"/>  Cisplatin (100 mg/m²) as neoadjuvant therapy plus continuous-infusion fluorouracil has also
been effective.<Reference refidx="6"/>  Single-agent cisplatin (50 mg/m<Superscript>2</Superscript>) was tested in a large trial and was ineffective.<Reference refidx="8"/></ListItem></OrderedList><Para id="_68">Because of the high incidence of microscopic node metastases, adjunctive
inguinal dissection of clinically uninvolved (negative) lymph nodes in
conjunction with amputation is often used for patients with poorly
differentiated tumors. Lymphadenectomy  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.  <Reference refidx="3"/><Reference refidx="4"/><Reference refidx="9"/><Reference refidx="10"/>
</Para><Para id="_146">To reduce the morbidity associated with prophylactic lymphadenectomy, dynamic sentinel node biopsy is used in patients with stage T2 and stage T3 clinically node-negative penile cancer.  One retrospective, single-institution study of 22 patients reported a  false-negative rate of 11%.<Reference refidx="11"/></Para><SummarySection id="_TrialSearch_58_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_58_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="4" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="5">Lynch DF, Pettaway CA: Tumors of the penis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Saunders, 2002, pp 2945-2947.</Citation><Citation idx="6">Fisher HA, Barada JH, Horton J, et al.: Neoadjuvant therapy with cisplatin and 5-fluorouracil for stage III squamous cell carcinoma of the penis. [Abstract] J Urol  143(4 Suppl): A-653, 352A, 1990.</Citation><Citation idx="7" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation><Citation idx="8" PMID="2642312" MedlineID="89068929">Gagliano RG, Blumenstein BA, Crawford ED, et al.: cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 141 (1): 66-7, 1989.</Citation><Citation idx="9" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="10" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation><Citation idx="11" PMID="16360457">Perdonà S, Autorino R, De Sio M, et al.: Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. Urology 66 (6): 1282-6, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_69"><SectMetaData><SpecificDiagnosis ref="CDR0000038252">stage IV penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Stage IV Penile Cancer</Title><Para id="_188"><Strong>Stage IV penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_90" Style="bullet"><ListItem>T4, Any N, M0</ListItem><ListItem>Any T, N3, M0</ListItem><ListItem>Any T, Any N, M1</ListItem></ItemizedList><Para id="_71">No standard treatment  exists that is curative for patients with stage IV penile cancer. 
Therapy is directed at palliation, which may be achieved either with surgery or
radiation therapy.
</Para><Para id="_72"><Strong>Treatment options:</Strong>
</Para><OrderedList id="_85" Style="Arabic"><ListItem>Palliative surgery may be considered for control of the local penile lesion
and even for the prevention of the necrosis, infection, and hemorrhage that
can result from neglected regional adenopathy.
</ListItem><ListItem>Radiation therapy may be palliative for the primary tumor, regional adenopathy,
and bone metastases.
</ListItem><ListItem>Clinical trials combining chemotherapy with palliative methods of local control
are appropriate. Tested chemotherapeutic drugs with some
efficacy include vincristine, cisplatin, methotrexate, and bleomycin.  The
combination of vincristine, bleomycin, and methotrexate has been effective both
as adjuvant and neoadjuvant therapy.<Reference refidx="2"/></ListItem></OrderedList><SummarySection id="_TrialSearch_69_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_69_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp 701–14.</Citation><Citation idx="2" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation></ReferenceSection></SummarySection><SummarySection id="_77"><SectMetaData><SpecificDiagnosis ref="CDR0000038263">recurrent penile cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Treatment of Recurrent Penile Cancer</Title><Para id="_78">Patients with locally recurrent disease can be treated with surgery or radiation therapy. 
If the initial treatment of radiation therapy fails,  patients often undergo
penile amputation.  Patients with nodal recurrences not controlled
by local measures are candidates for phase I and phase II clinical trials testing new
biological and chemotherapeutic agents.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/></Para><SummarySection id="_TrialSearch_77_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_77_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation><Citation idx="2" PMID="6206239" MedlineID="84292484">Ahmed T, Sklaroff R, Yagoda A: Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 132 (3): 465-8, 1984.</Citation><Citation idx="3" PMID="1719241" MedlineID="92046406">Dexeus FH, Logothetis CJ, Sella A, et al.: Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146 (5): 1284-7, 1991.</Citation><Citation idx="4">Fisher HA, Barada JH, Horton J, et al.: Neoadjuvant therapy with cisplatin and 5-fluorouracil for stage III squamous cell carcinoma of the penis. [Abstract] J Urol  143(4 Suppl): A-653, 352A, 1990.</Citation><Citation idx="5" PMID="2297633" MedlineID="90124109">Hussein AM, Benedetto P, Sridhar KS: Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 65 (3): 433-8, 1990.</Citation></ReferenceSection></SummarySection><SummarySection id="_97"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (05/07/2025)</Title><Para id="_98">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_234">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062897#_AboutThis_1" url="/types/penile/hp/penile-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of penile cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Penile Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Juskaran S. Chadha, DO (Moffitt Cancer Center)</ListItem><ListItem>Jad Chahoud, MD, MPH (Moffitt Cancer Center)</ListItem><ListItem>Timothy Gilligan, MD (Cleveland Clinic Taussig Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Penile Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/penile/hp/penile-treatment-pdq">https://www.cancer.gov/types/penile/hp/penile-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389381]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateLastModified>2025-05-07</DateLastModified></Summary>
